#None #London #Alimentiv #Ultrasound Training #IBUS

Expanding Horizons in Clinical Trials: Alimentiv and IBUS Partnership

In a significant development for the field of gastroenterological research, Alimentiv Inc., a worldwide leader in clinical research, has announced an expansion of its exclusive partnership with the International Bowel Ultrasound Group (IBUS). This collaboration aims to enhance the training and certification of ultrasound imaging professionals within the realm of clinical trials, ultimately facilitating better healthcare outcomes for patients with inflammatory bowel diseases (IBD).

IUS-STAR: A New Certification Program

The newly launched IUS Standardized Training and Acquisition for Research (IUS-STAR) program is a structured and scalable training initiative designed for sonographers, radiologists, and technologists involved in clinical trials. IUS-STAR focuses on delivering advanced and accelerated training in idiopathic ultrasound techniques, which are critical for the success of clinical studies.

This innovative program combines user-friendly online learning with applied scanning data acquisition and iterative image review. By offering targeted feedback and support, IUS-STAR aims to bolster operators' confidence and competence in producing high-quality, protocol-compliant images, thereby supporting the overall success of clinical trial outcomes in IBD.

Stephanie Gonzalez, the Operations Director at Alimentiv, emphasized the program's significance: "IUS-STAR perfectly illustrates the synergistic benefits of this partnership—combining IBUS's scientific leadership with our global operational infrastructure, including the Notō Case Manager technology for image review and quality control. This advancement leads to expedited site setup and a growing number of sites prepared for clinical trials focusing on IBD."

Advancing Clinical Outcomes

Since the inception of their partnership in 2022, Alimentiv and IBUS have introduced cutting-edge intrauterine ultrasound (IUS) expertise into clinical trial environments across more than 34 countries. They have made significant strides in standardizing and incorporating IUS as a non-invasive imaging modality in IBD research.

Kerri Novak, President of IBUS, noted: "Utilizing bowel ultrasound—a reproducible and well-tolerated assessment tool for evaluating intestines in clinical trials—marks a significant milestone. It improves not only the identification of patients with active disease but also increases patient accessibility and participation in clinical trials. Furthermore, cross-sectional imaging is vital for advancing our understanding of pathological processes and therapeutic responses."

By collaborating closely with Alimentiv, IBUS is excited to offer a comprehensive training pathway that ensures the highest quality and consistency of imaging acquired for clinical trials. This program will provide participants with invaluable opportunities to study cases alongside experts, receive constructive feedback and guidance, and display their proficiency through certification undertakings.

The IUS-STAR program plays a critical role in preparing study sites and acquiring standardized images, facilitating access to high-quality ultrasound data during clinical trials. The partnership aspires to increase awareness and participation in this crucial initiative.

Commitment to Non-Invasive Disease Monitoring

As interest in non-invasive disease monitoring continues to grow, Alimentiv and IBUS remain dedicated to promoting education, standardization, and innovation within the field of bowel ultrasound. These efforts are intended to support researchers, study sites, sponsors, and ultimately patients suffering from gastrointestinal conditions.

Professionals eager to learn more about the IUS-STAR program can reach out via email at [email protected]

About Alimentiv

Alimentiv is a global Contract Research Organization (CRO) focused on gastroenterology, advancing gastrointestinal clinical trial science and medical research for over three decades. It offers a comprehensive range of services, specializing in clinical, medical imaging, and precision medicine solutions while partnering with pharmaceutical and biotechnology industries to develop new therapies, leading to improved outcomes for all patients affected by gastrointestinal disorders. Headquartered in London, Ontario, Canada, Alimentiv operates globally across Canada, the United States, Europe, Asia-Pacific, and Latin America. For further information, visit alimentiv.com.

About IBUS

The International Bowel Ultrasound Group (IBUS) is a non-profit organization that unites international experts in bowel ultrasound and inflammatory bowel diseases, aiming to promote bowel ultrasound usage. IBUS has pioneered global training initiatives in bowel ultrasound aimed at gastroenterologists and specialists treating patients with IBD. The organization also provides a platform for collaborative research in the IBD field, intending to advance research, education, and clinical applicability of bowel ultrasound to enhance personalized patient care and outcomes. For more information, visit ibus-group.org.